AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9829444
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (CA) 250 mg b.i.d. for 10 days
Trial: 9829444
Drug: Ciprofloxacin (CIP)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (CIP) 500 mg b.i.d. for 10 days
Trial: 7917535
Drug: Etretinate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretinate (50 mg/day for the first month, followed by 25 mg/day for the following months)
Trial: 332345
Drug: Cycle-active therapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle-active therapy (methotrexate, cytosine arabinoside, and 6‐thioguanine)
Trial: 31752543
Drug: Immunoelectron microscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoelectron microscopy (IEM) with gold‐labelled antibodies against kappa light chains, lambda light chains, transthyretin and amyloid A
Trial: 25409112
Drug: Conventional Diagnostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Diagnostic and Treatment Outpatient Medical Care (CONV) approach
Trial: 23341418
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (20-minute interventions pre- and post-surgery)
Trial: 3441105
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of timolol 0.5% and pilocarpine 2%
Trial: 3441105
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of timolol 0.5% and pilocarpine 4%
Trial: 21982456
Drug: Real-time automated
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time automated electronic medical record alerts for patients with estimated glomerular filtration rates <45 mL/min/1.73 m(2) recommending renal referral and urine albumin quantification if not done within the prior year.
Trial: 6742895
Drug: Ice therapy
RxNorm normalized name: Ice Therapy
DrugBank: Levomenthol (DB00825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ice therapy
Trial: 14756914
Drug: 4800 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4800 microg retinol (vitamin A) + 120 mg Fe + 500 microg folic acid
Trial: 14756914
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg Fe + 500 microg folic acid (without vitamin A)
Trial: 11359657
Drug: rHuIL-12 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuIL-12 administered by subcutaneous injection at a maintenance dose of 1.25 microg/kg on days 1, 8, and 15 of each 28-day cycle.
Trial: 11359657
Drug: IFN-alpha 2a
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha 2a administered at 9 million units by subcutaneous injection three times per week.
Trial: 8503670
Drug: Autohaler inhalation
RxNorm normalized name: pirbuterol
DrugBank: Pirbuterol (DB01291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Autohaler inhalation device
Trial: 22562730
Drug: Concurrent strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent strength and continuous running training (SCR)
Trial: 22562730
Drug: Concurrent strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent strength and interval running training (SIR)
Trial: 22562730
Drug: Concurrent strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent strength and continuous cycle ergometer training (SCE)
Trial: 19709658
Drug: Non-specific immunomodulation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-specific immunomodulation therapy (IMT), autologous blood exposed to oxygen/ozone gas mixture by intragluteal injection, administered on day 1, 2, 7, and once a week thereafter for at least 22 weeks.
Trial: 19709658
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered to control group (n=74).
Trial: 19709658
Drug: Non-specific immunomodulation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-specific immunomodulation therapy (IMT).
Trial: 16296712
Drug: Amlodipine (5‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5‐10 mg once daily)
Trial: 8151609
Drug: Nifedipine retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine retard (20‐40 mg twice daily)
Trial: 18817348
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy
Trial: 31179505
Drug: Cervical headgear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical headgear with heavy force (500 g)
Trial: 31179505
Drug: Cervical headgear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical headgear with light force (300 g)
Trial: 17562336
Drug: GnRH agonist,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH agonist, low‐dose GnRH antagonist, and estradiol valerate followed by recombinant FSH, 600 IU/day (n = 72)
Trial: 17562336
Drug: GnRH agonist,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH agonist, low‐dose GnRH antagonist, and estradiol valerate followed by recombinant FSH, 750 IU/day (n = 65)
Trial: 12404072
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg hydrocodone/1.5 mg homatropine
Trial: 12404072
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg hydrocodone/3 mg homatropine
Trial: 12404072
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg hydrocodone/6 mg homatropine
Trial: 12955305
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg morphine
Trial: 9700978
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg lorazepam
Trial: 10705173
Drug: Teprenone 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teprenone 1.5 g/day for 8 weeks (PHG(+)‐t)
Trial: 9552427
Drug: Slow-dissolving formulation
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-dissolving formulation
Trial: 9552427
Drug: Medium-dissolving formulation
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dissolving formulation
Trial: 9552427
Drug: Fast-dissolving formulation
RxNorm normalized name: melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fast-dissolving formulation
Trial: 20649056
Drug: Ciprofloxacin 400
RxNorm normalized name: ciprofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 400 mg intravenously every 8 h
Trial: 20649056
Drug: Ciprofloxacin 400
RxNorm normalized name: ciprofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 400 mg intravenously every 12 h
Trial: 16934148
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics via the respiratory tract (gentamicin, polymyxins, tobramycin, ceftazidime)
Trial: 1597846
Drug: DTZ SR/HCTZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTZ SR/HCTZ (60/6.25 mg)
Trial: 1597846
Drug: DTZ SR/HCTZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTZ SR/HCTZ (90/6.25 mg)
Trial: 1597846
Drug: HCTZ (6.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ (6.25, 6.25, 12.5 mg twice daily)
Trial: 29153273
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (8 sessions)
Trial: 26869076
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Suicide Prevention (CBSP) therapy
Trial: 17909305
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy for 12 weeks followed by medroxyprogesterone acetate for 2 weeks
Trial: 15516532
Drug: Sildenafil (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (3 x 40 mg/day for 6 days)
Trial: 9459371
Drug: Low-C diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-C diet (50 mg ascorbic acid/d)
Trial: 9459371
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ascorbic acid/d (high-C diet)
Trial: 7629982
Drug: Azithromycin (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1.0 g as a single oral dose)
Trial: 7629982
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg taken orally twice daily for 7 days)
Trial: 2775615
Drug: Levodopa (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (50 mg) administered intravenously
Trial: 2775615
Drug: Levodopa (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (250 mg) administered orally
Trial: 2775615
Drug: Levodopa (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (50 mg) administered intravenously in the presence of carbidopa
Trial: 30066465
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (20 mL bupivacaine 0.5% + 2 mL normal saline)
Trial: 24715230
Drug: Subconjunctival and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival and/or intrastromal injections of 5 mg/0.2 ml Bevacizumab (3 injections)
Trial: 24715230
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Bevacizumab injections)
Trial: 21777886
Drug: Zotarolimus-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zotarolimus-eluting stents with prolonged drug release (ZES-SR)
Trial: 16454147
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (identical to treatment)
Trial: 20089774
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment and placebo groups
Trial: 27355400
Drug: Testosterone (T)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone (T) gel
Trial: 11932266
Drug: Dihydrotestosterone (DHT)
RxNorm normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Stanolone acetate (DB13951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrotestosterone (DHT) gel
Trial: 10808696
Drug: Continuous hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous hormonal replacement therapy (HRT) with conjugated equine estrogen 0.625 mg/day and medroxyprogesterone acetate 2.5 mg/day for 21.3 +/- 9.5 months.
Trial: 10808696
Drug: No hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormonal replacement therapy (Control group).
Trial: 1599726
Drug: Two-visit intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-visit intervention group (risk assessment, support, cessation date setting, self-help literature, nicotine gum prescription)
Trial: 4060998
Drug: Intramuscular opiates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular opiates post-operatively
Trial: 3933262
Drug: Intramuscular group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular group
Trial: 27881624
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and commitment therapy self-help intervention
Trial: 16495243
Drug: Telavancin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telavancin at 10 mg/kg intravenously every 24 h
Trial: 16495243
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (antistaphylococcal penicillin at 2 g q6h or vancomycin at 1 g q12h)
Trial: 15535882
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (patient education and exercise therapy)
Trial: 3331041
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg b.i.d. (suspended in saline)
Trial: 3331041
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg t.i.d. (suspended in saline)
Trial: 3331041
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg b.i.d. (suspended in 1% lidocaine)
Trial: 23093347
Drug: Teriparatide (28.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (28.2 or 56.5 μg injection)
Trial: 17257460
Drug: Modafinil (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100-400 mg, administered once daily or as a divided dose)
Trial: 9589355
Drug: Indole-3-carbinol (I3C)
DrugBank: Indole-3-carbinol (DB12881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indole-3-carbinol (I3C) 300 mg and 400 mg high-dose (HD)
Trial: 9589355
Drug: Indole-3-carbinol (I3C)
DrugBank: Indole-3-carbinol (DB12881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indole-3-carbinol (I3C) 50 mg, 100 mg, 200 mg low-dose (LD)
Trial: 15735366
Drug: High-genistein isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-genistein isoflavone extract (HGI, 150 mg/day)
Trial: 2096041
Drug: Homeopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic treatment (Opium and Raphanus)
Trial: 29412008
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: unenhanced CT with 100 kVp, 200 mA and contrast-enhanced CT with spectral CT mode using low dose protocols.
Trial: 29412008
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: average radiation dose of 6.18 mSv.
Trial: 18849625
Drug: 3-ml volume
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-ml volume of anesthetic solution
Trial: 18849625
Drug: 5-ml volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ml volume of anesthetic solution
Trial: 18849625
Drug: 7-ml volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-ml volume of anesthetic solution
Trial: 9690694
Drug: Oral mCPP
RxNorm normalized name: MCPP
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mCPP (0.5 mg/kg)
Trial: 7578657
Drug: Intravenous mCPP
RxNorm normalized name: MCPP
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous mCPP (0.1 mg/kg over 20 min)
Trial: 2267922
Drug: Hydrocortisone and
RxNorm normalized name: hydrocortisone and mydriatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone and oral prednisolone for 5 days
Trial: 26197184
Drug: H7N9 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H7N9 vaccine with MF59 adjuvant (15 µg hemagglutinin)
Trial: 21368590
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine in HIV-infected pregnant women
Trial: 21368590
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine in uninfected pregnant women
Trial: 11535325
Drug: Zanamivir 20
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanamivir 20 mg daily for 14 days
Trial: 3058133
Drug: Muroctasin (MDP-Lys(L18))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muroctasin (MDP-Lys(L18)) at a dose of 200 micrograms, administered subcutaneously starting on day 4 after chemotherapy for 10 days
Trial: 3058133
Drug: Control cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control cycle (standard chemotherapy protocol)
Trial: 11598429
Drug: Cognitive-Behavioural Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioural Therapy (CBT)
Trial: 28086934
Drug: Real electroacupuncture/moxibustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real electroacupuncture/moxibustion treatments
Trial: 28086934
Drug: Sham electroacupuncture/moxibustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham electroacupuncture/moxibustion treatments
Trial: 26094857
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonist exenatide
Trial: 10357429
Drug: 24% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% sucrose solution
Trial: 10922432
Drug: Calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonist therapy (diltiazem and verapamil)
Trial: 1531673
Drug: Cl2MDP (2‐dichloromethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cl2MDP (2‐dichloromethylene bisphosphonate), 600 mg in 500 mL of normal saline
Trial: 1531673
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mL of normal saline)
Trial: 30665438
Drug: Integral movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integral movement therapy, 20 supervised sessions over 10 weeks, twice per week, approximately 1 hour per session.
Trial: 30665438
Drug: Conventional local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional local movement therapy, 20 supervised sessions over 10 weeks, twice per week, approximately 1 hour per session.
Trial: 19539384
Drug: allopurinol 300
RxNorm normalized name: allopurinol 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: allopurinol 300 mg daily
Trial: 15848559
Drug: Modified release
RxNorm normalized name: MODIFIED RELEASE CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified release tacrolimus (MR tacrolimus) once daily (qD)
Trial: 15848559
Drug: Prograf twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prograf twice a day
Trial: 8045844
Drug: Propranolol (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (240 mg/day)
Trial: 2808215
Drug: Meropenem 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 0.25 g
Trial: 2808215
Drug: Meropenem 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 0.5 g
Trial: 2808215
Drug: Meropenem 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 1.0 g
Trial: 7013721
Drug: Oral mexiletine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mexiletine (200 mg 4 times daily)
Trial: 30969203
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia
Trial: 17876852
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide spray (1-2 sprays, maximum of 4 times per day)
Trial: 17876852
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide spray
Trial: 7740443
Drug: Dermatan sulphate
RxNorm normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermatan sulphate 300 mg twice daily
Trial: 7740443
Drug: Standard prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prophylactic agents
Trial: 25771840
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of placebo (olive oil)
Trial: 23534988
Drug: Nanoparticle albumin-bound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) administered every 3 weeks (q3w)
Trial: 20666686
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (500 mg daily, 4 consecutive days per month for 3 consecutive months)
Trial: 19187076
Drug: AVE5026 (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVE5026 (5, 10, 20, 40, or 60 mg)
Trial: 19187076
Drug: AVE5026 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVE5026 (60 mg)
Trial: 20458441
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg
Trial: 1557967
Drug: fucithalmic drops
RxNorm normalized name: Fucithalmic
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fucithalmic drops twice daily
Trial: 1557967
Drug: chloramphenicol (chlormycetin)
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chloramphenicol (chlormycetin) ointment twice daily